MET and non-small cell lung carcinoma: The initial preclinical link between MET and resistance to third-generation EGFR-TKIs came from our observation that an EGFR mutant (EGFRm) NSCLC cell line with acquired resistance to erlotinib (HCC827/ER), which has amplified MET gene and hyperactivated MET protein, was cross-resistant to both osimertinib and rociletinib.